Graviton

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Synopsys infographic showing its more-than-$1 billion multi-year Amazon agreement covering silicon IP, chip-design technology and AI engineering tools, alongside AWS custom chips such as Nitro, Graviton and Trainium.

Synopsys lands $1bn-plus Amazon chip IP deal as AWS custom silicon expands

The multi-year agreement makes Amazon a lead customer for Synopsys’ application-optimised silicon IP and ties the chip-design specialist more directly to AWS processors including Graviton and Trainium.

bySrinath

October 1, 2026

AWS bets on NVLink Fusion and Trainium4 to reshape AI infrastructure at hyperscale

AWS integrates NVIDIA NVLink Fusion into Trainium4 and launches AI Factories with Blackwell GPUs. Explore how this partnership reshapes enterprise AI compute.

byVenkatesh

December 3, 2025

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Synopsys lands $1bn-plus Amazon chip IP deal as AWS custom silicon expands

AWS bets on NVLink Fusion and Trainium4 to reshape AI infrastructure at hyperscale

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

SAMILBIO expands Chaeyun skincare with two November launches as K-beauty exports reach $11.1bn

Schneider Electric Infrastructure (SCHNEIDER) shares fall 3.5% despite new factory expansion: What will November results reveal?

Haleon (HLN) near 319p: Does a 15% share-price crash make its valuation attractive after the growth downgrade?

Ethan Allen will split CEO and chair roles, but who gets to choose Farooq Kathwari’s successor?